## Current research agenda for pharmacy leaders

| Торіс                          | What we're researching  | Why it matters   |
|--------------------------------|---|--|
| Specialty pharmacy trends      | <ul> <li>What are the current dynamics impacting the specialty pharmacy market?</li> <li>What key trends do we see in health system-owned specialty pharmacies?</li> <li>What strategies do health system executives deploy in organizations that see substantial value from their specialty pharmacies?</li> </ul>   | <ul> <li>Specialty drugs now account for over half of U.S. drug<br/>spending. Health system-owned specialty pharmacies can<br/>improve patient outcomes and financial margins, but leaders<br/>must navigate accreditation, limited distribution, and payer<br/>dynamics to succeed.</li> </ul>          |
| Infusion market trends         | <ul> <li>What are the market forces shaping infusion care?</li> <li>How are health systems navigating a shifting drug pipeline, payer pressures, and heightening competition?</li> </ul>  | <ul> <li>Infusion services are a key revenue and care delivery area.         Navigating market headwinds and optimizing operations helps pharmacy leaders improve efficiency, reduce costs, and enhance patient access.     </li> </ul>  |
| Cancer patient travel analysis | <ul> <li>How many cancer patients leave their market to receive cancer care?</li> <li>What other care do they travel for? How far are they willing to go?</li> <li>Which patients are most likely to travel?</li> </ul>   | <ul> <li>To address leakage points, pharmacy leaders need to<br/>understand for what services patients are leaving their markets.<br/>This claims-based analysis will help pharmacy leaders<br/>understand the geographic scale on which they may be able to<br/>compete for cancer patients.</li> </ul> |
| Radiopharmaceuticals           | <ul> <li>Which health systems should deliver radiopharmaceuticals?</li> <li>How should health systems approach radiopharmaceuticals delivery? <ul> <li>How should they prepare to launch a radiopharmaceuticals program?</li> <li>What are best practices for delivering radiopharmaceuticals?</li> <li>What are the considerations for expanding an existing program?</li> </ul> </li> </ul> | <ul> <li>Pharmacy leaders must assess the complexities of<br/>radiopharmaceutical delivery to decide whether – and how – to<br/>invest in this growing aspect of cancer care.</li> </ul>   |

